| Better Choice (OTCQB: BTTR) Receives 15 Product Import Registrations from Chinese Ministry of Agriculture and Rural Affairs |
| |
|
Better Choice Company (OTCQB: BTTR) announced that one of its subsidiaries, Halo, Purely for Pets, recently received Product Import Registrations for 15 Holistic Dog and Cat Food Diets from the Ministry of Agriculture and Rural Affairs of China. Halo is the only real, whole meat based US pet food brand to receive these registrations in the latest announcement from the Ministry.
Why It Matters: Chinese shoppers are set to spend $7 billion on their pets by 2022, according to Reuters. Based on data from Euromonitor, dog and cat food sales in China were $2.2 billion in 2018 and are expected to reach $6.1 billion in 2025, a 28.9% CAGR. Growing demand is being driven by increasing disposable income, changes in consumer lifestyle, and increased pet ownership. While the market is still relatively young in terms of pet ownership, it is growing rapidly.
Key Quote: “Our registrations and authorizations to sell through both retail and online channels in China significantly increases our reach. When combined with our solid marketing foundation and our sophisticated go to market operations through our partner Penefit International we are well positioned to build out our distribution.” – Werner von Pein, CEO
The Backstory: Better Choice is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. We take an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings and position our portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. We have a demonstrated, multi-decade track record of success selling trusted animal health and wellness products and leverage our established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. We sell the majority of our dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats.
Disclosure
Better Choice (BTTR) is a client of RedChip Companies, Inc. BTTR agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2020, increasing to $15,000 monthly in August 2020, and $20,000 monthly in October 2020, for RedChip investor awareness services.
|
|
| |
|
| CytoDyn (OTCQB: CYDY) Receives BLA Acknowledgment Letter from FDA |
| |
|
CytoDyn (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the U.S. Food and Drug Administration (FDA) advised the Company, subject to its ongoing review, it could receive its “PDUFA date” on July 10, 2020.
Why it Matters: Under the Prescription Drug User Fee Act (PDUFA), the FDA sets a goal date for the agency to complete its review of a new drug application; this date is commonly referred to as the “PDUFA date.” The FDA’s standard review time for new drug applications is 10 months. The Company’s drug candidate, leronlimab, was previously granted Fast Track designation by the FDA and the BLA was granted rolling review. The Company recently filed for Priority Review designation with the intent to reduce the FDA’s review time to six months. The FDA informs the applicant of a Priority Review designation within 60 days.
Key Quote: “We are very encouraged by our recent correspondence with the FDA and remain hopeful of a PDUFA date to be announced by the agency on July 10. The review of our BLA could not be more timely, as our other trials for COVID-19 are approaching two important milestones and should the outcome be successful, we believe the information in this BLA could be very useful in expediting approval of leronlimab to treat COVID-19, as well as HIV.” – Nader Pourhassan, Ph.D., President and CEO
The Backstory: CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020.
Disclosure
CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $7,500 quarterly cash fee, beginning in May 2020, for RedChip investor awareness services. The CEO of RedChip Companies owns 3400 shares of CYDY.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) Announces Pricing of Public Offering |
| |
|
Piedmont Lithium (NASDAQ: PLL) announced the pricing of an underwritten public offering of 1,800,000 American Depositary Shares, each representing 100 of its ordinary shares ("Public Offering"), at a price per ADS to the public of $6.30, for aggregate gross proceeds of $11,340,000.
Why It Matters: Proceeds from the offerings will be used to continue development of the Company’s Piedmont Lithium Project, including a definitive feasibility study, testwork, permitting, and ongoing land consolidation, and for general corporate purposes.
The Backstory: Location is one of the standout features of the Piedmont project, with access to excellent infrastructure and transport options, close proximity to existing lithium chemical processing facilities operated by Livent (NYSE: LTHM) and Albemarle (NYSE: ALB), and within reach of 13 auto manufacturing facilities. Compared to Australian- and Canadian-based projects, North Carolina offers a significantly lower-cost operating environment (labor, power/gas/diesel, transport), which is further boosted by the absence of government royalties and a low tax rate environment. Lithium is on the US Government’s Critical Minerals list, giving the project significant strategic value as being the only conventional US lithium development project.
Disclosure
Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a quarterly cash fee of $20,000, beginning in April 2019, for 12 months of RedChip investor awareness services.
|
|
| |
|
| Esports Entertainment Group (NASDAQ: GMBL) Receives Additional $4.4M From Exercise of Warrants for a Total of Approximately $6.2M Since IPO |
| |
|
Esports Entertainment Group (NASDAQ: GMBL), a licensed online gambling company with a focus on esports wagering and 18+ gaming, announced the receipt of approximately $4,375,000 from the exercise of warrants.
Why It Matters: Combined with the Company’s press release on May 26, in which the Company announced the receipt of approximately $1,860,000 from the exercise of warrants, the Company has received an aggregate of approximately $6,235,000 as of June 8, 2020 from the exercise of warrants by investors participating in the Company’s IPO.
Key Quote: “Today’s announcement significantly bolsters our financial strength and resources necessary to execute our business plan.” - Grant Johnson, CEO
The Backstory: Esports Entertainment Group is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in Curacao, Kingdom of the Netherlands.
Disclosure
Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a $4,000 monthly cash fee, beginning in June 2018, and 225,000 shares of Rule 144 stock for RedChip investor awareness services.
|
|
| |
|
| Can-Fite BioPharma (NYSE American: CANF) to Advance Piclidenoson into Phase II COVID-19 Trial in U.S. |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that in response to Can-Fite’s Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the prospective use of Piclidenoson to treat patients suffering from COVID-19. The FDA’s response allows Can-Fite to proceed to the next step of formally submitting an IND for Piclidenoson in this indication.
Why It Matters: The planned Phase II trial will evaluate the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for COVID-19 infected patients with moderate-to-severe symptoms.
Key Quote: “We are grateful for the thoughtful and comprehensive guidance from the FDA. Using the FDA’s feedback on our clinical trial, we anticipate submitting an IND shortly. We believe that Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the potential treatment of COVID-19.” – Dr. Pnina Fishman, CEO
The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Piclidenoson has been approved for a pilot clinical trial in Israel to treat COVID-19 infected patients with moderate-to-severe symptoms. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Announces Subscription Program to Enable Law Enforcement Departments to Purchase Body Cameras |
| |
|
Digital Ally (NASDAQ: DGLY) which develops, manufactures and markets advanced video recording products for law enforcement, emergency management, fleet safety and security, announced the launch of a body camera subscription program as a response to high demand for video evidence technology for police and other first responder personnel.
Why It Matters: The company has determined that many departments do not have adequate funding for video evidence technology. The new subscription program will not only provide an opportunity to pay off the units over time, but in many cases, will offer packages that require no down payment.
Key Quote: “Body cameras are critically important to the safety and security of all concerned and we can’t let restricted funding get in the way of outfitting law enforcement, military and first responders with this technology.” – Stan Ross, CEO
The Backstory: Headquartered in Lenexa, KS, Digital Ally specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include vehicle and body cameras, flexible software storage, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, beginning in September 2017, for RedChip investor awareness services.
|
|
| |
|
| 1847 Holdings (OTC: EFSH) Acquires Leading Bay Area Appliance Retailer |
| |
|
1847 Holdings (OTC: EFSH), a unique publicly traded holding company platform that acquires lower-middle market, American companies at attractive valuations, today announced it completed its acquisition of Asien’s Appliance (www.asiensappliance.com), a California-based appliance retailer that generated approximately $8.9 million (unaudited) and $13.3 million (unaudited) of revenues in 2018 and 2019, respectively.
Why It Matters: The household appliance market in the US is forecasted to exceed $21 billion in 2020 and is expected to grow at a CAGR of 13.7%, reaching $40 billion in 2025, according to data from Statista.
Key Quote: “Asien’s is well-known and highly respected brand and one of the oldest appliance stores in its market, providing a solid foundation as we leverage our team’s extensive experience with previous high-growth retail operations, such as Hatworld/Lids, Teavana and Regional Management Corporation to grow market share and build a more dominant presence in the surrounding area.” – Ellery Roberts, CEO
The Backstory: 1847 Holdings operates American companies it acquires at attractive valuations, leveraging its management team’s extensive experience gained at leading investment firms, such as Colony Capital, Lazard Freres and Saunders, Karp & Megrue, to grow operations and create value. 1847 Holdings seeks to generate returns for shareholders in the future through consistent, annual distributions of operating subsidiary income and capital appreciation resulting from the timely sale of operating subsidiaries.
Disclosure
1847 Holdings (EFSH) is a client of RedChip Companies, Inc. EFSH agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in November 2019, and 100,000 restricted common shares of EFSH stock for 12 months of RedChip investor awareness services.
|
|
| |
|
| Recruiter.com (OTCQB: RCRT) Index Presented Reasons for Job Market Optimism |
| |
|
Recruiter.com Group (OTCQB: RCRT), a leading hiring platform for the world's largest network of small and independent recruiters, announced the results of the Recruiter Index® for May 2020. Evan Sohn, Recruiter.com Group Executive Chairman, presented the results live on CNBC's Special Report: Markets in Turmoil, on Wednesday, 5/27/2020.
Key Quote: “We are glad that we were able to spot and report on positive trends in the job market ahead of the jobs report on Friday, which showed the economy gaining 2.5 million jobs in May and the unemployment rate declining to 13.3 percent, from 14.7 percent in April. Our hiring platform, with over 25,000 recruiters, gives us special insight into areas of business growth. We look forward to continuing to gather and use important job market data, as the country vectors toward re-opening.” – Evan Sohn, Executive Chairman
The Backstory: Recruiter.com's Recruiter Index Report revealed that across nearly every industry, surveyed recruiters are reporting upticks in job requirement loads — and predicting further improvements over the coming months as the economy re-opens. A clear majority of surveyed recruiters across industries — 60.4 percent — believe their job requirement loads will increase in the next 90 days, compared to 38.5 percent in April.
Disclosure
Recruiter.com (RCRT) is a client of RedChip Companies, Inc. RCRT agreed to pay RedChip Companies, Inc. 9,000 shares of RCRT common stock and a $7,500 monthly cash fee, beginning in June 2020 for RedChip investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"There is a certain degree of logic to the stock market and the psychology that rules it when one takes into account the emotions of greed and fear."
- Jeffrey B Little and Lucien Rhodes, Understanding Wall Street, 5th Edition |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
|
